Gout

The data reported significant improvements in serum urate (sUA) following 12 weeks of treatment.

Given the growing evidence that patients with gout are at an increased risk of developing cardiovascular disease, accurately screening patients and identifying potential risk factors is of critical importance.

Tarun Sharma, MD, a rheumatologist with the Allegheny Health Network who helped author the American College of Rheumatology's most recent gout guidelines, sits down to provide perspective on the latest updates in gout from 2022, including new trial data, regulatory news and updates, and a glimpse into what he is most excited for in 2023.

Dr. John Botson explains that gout is not a patient problem, it's a disease problem, and it needs to be approached as a lifelong rheumatic disease as opposed to an episodic one.

Investigator Dr. John Botson spoke on the phase 4 MIRROR study that supported the FDA approval for pegloticase combined with methotrexate for patients with uncontrolled gout.

The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.

Investigators identified novel biomarkers of incident gout and replicated novel metabolomic biomarkers of gout, including plasma levels of glycoprotein acetyls.

Differences among baseline clinical and laboratory characteristics between cases and controls were observed in those with a presence of subcutaneous tophi and higher serum urate levels.

John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.

While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.

“Understanding the drivers of this increased risk in women with gout warrants further investigation in larger datasets," investigators stated.

Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2022.

Supported self-management approaches have been shown to benefit patients with chronic health conditions, including gout.

“The effects of coffee consumption on SUA levels and gout risk are controversial,” investigators explained. “There have hitherto been no reports based on its effects that consider pleiotropy.”

Dr. LaMoreaux believes that to treat gout in patients with proper medications and therapies, doctors must first establish trust and combat the stigma surrounding this painful form of arthritis.

Adjusting lifestyle factors can reduce the risk of gout in men.

Gout is not only an intermittent disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive, says Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics. As a nephrologist, he sees gout as a kidney disease. In this interview, he explains why.

Managing CTDs may have an overall benefit on cardiovascular health.

It is necessary to continue urate-lowering therapy in the inpatient setting to decrease the risk of gout flare in hospitalized patients.

Gout must be treated every day rather than as a single event.

John Botson, MD, defines gout and how it can be treated.

A clinical rheumatologist breaks down how the combination therapy can be used to treat uncontrolled gout.

More patients maintain therapeutic response when treated concomitantly with methotrexate and pegloticase when compared to those who use pegloticase alone.

Dapansutrile has substantial potential for further development for the treatment of gout flares and other NLRP3-mediated diseases.

Compared with other antihypertensive medications, amlodipine was found to reduce risk of gout in older patients.

Abdul Abdellatif, MD, discusses during Kidney Week some treatment options for patients with gout.

Brian LaMoreaux, MD, medical director with Horizon Therapeutics, discusses response to concurrent methotrexate and pegloticase use for treating uncontrolled gout.